Loading...
Loading...
Amicus Therapeutics
FOLD shares dropped 46.97% to $3.06 in pre-market trading. Amicus Therapeutics and GlaxoSmithKline plc
GSK today announced the 6-month primary treatment period results from the first Phase 3 global registration study.
Allscripts Healthcare Solutions
MDRX shares fell 16.48% to $8.92 in the pre-market trading. Allscripts appointed Paul Black as its CEO.
Accenture plc
ACN dipped 5.21% to $66.73 in the pre-market session. Accenture projects Q2 revenue of $6.9 billion of $7.15 billion, versus analysts' estimates of $7.14 billion.
Bed Bath & Beyond
BBBY dipped 4.86% to $57.35 in the pre-market session. Bed Bath & Beyond issued downbeat fourth-quarter earnings forecast. The company's board also authorized a new $2.5 billion share repurchase program.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in